Cardiol Therapeutics Inc. reports clinical, financing, and corporate updates as a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead oral small-molecule candidate, CardiolRx, modulates inflammasome pathway activation associated with inflammation and fibrosis in pericarditis, myocarditis, and heart failure.
Recurring developments include the MAVERIC program in recurrent pericarditis, the completed ARCHER Phase II study in acute myocarditis, peer-reviewed publication of clinical data, U.S. trial-network updates, intellectual-property disclosures, and development of CRD-38 for heart failure and other inflammatory heart diseases. Company news also covers bought deal financings, common share and warrant offerings, annual operating updates, and healthcare conference presentations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.